EP2200431A4 - Compositions et procédés nouveaux pour le traitement du cancer - Google Patents
Compositions et procédés nouveaux pour le traitement du cancerInfo
- Publication number
- EP2200431A4 EP2200431A4 EP08830633A EP08830633A EP2200431A4 EP 2200431 A4 EP2200431 A4 EP 2200431A4 EP 08830633 A EP08830633 A EP 08830633A EP 08830633 A EP08830633 A EP 08830633A EP 2200431 A4 EP2200431 A4 EP 2200431A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- cancer treatment
- novel compositions
- compositions
- novel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/74—Naphthothiophenes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL16156278T PL3067054T3 (pl) | 2007-09-10 | 2008-09-10 | Nowe kompozycje i sposoby leczenia nowotworów |
EP16156278.0A EP3067054B1 (fr) | 2007-09-10 | 2008-09-10 | Compositions et procédés nouveaux pour le traitement du cancer |
DK16156278.0T DK3067054T3 (da) | 2007-09-10 | 2008-09-10 | Nye sammensætninger og fremgangsmåder til behandling af cancer |
SI200831655A SI2200431T1 (sl) | 2007-09-10 | 2008-09-10 | Sestave in metode za zdravljenje raka |
HRP20160949TT HRP20160949T1 (hr) | 2007-09-10 | 2016-07-26 | Novi sastavi i metode za liječenje karcinoma |
CY20211100258T CY1123986T1 (el) | 2007-09-10 | 2021-03-24 | Νεες συνθεσεις και μεθοδοι για τη θεραπεια του καρκινου |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97114407P | 2007-09-10 | 2007-09-10 | |
US1337207P | 2007-12-13 | 2007-12-13 | |
PCT/US2008/075906 WO2009036101A1 (fr) | 2007-09-10 | 2008-09-10 | Compositions et procédés nouveaux pour le traitement du cancer |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16156278.0A Division-Into EP3067054B1 (fr) | 2007-09-10 | 2008-09-10 | Compositions et procédés nouveaux pour le traitement du cancer |
EP16156278.0A Division EP3067054B1 (fr) | 2007-09-10 | 2008-09-10 | Compositions et procédés nouveaux pour le traitement du cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2200431A1 EP2200431A1 (fr) | 2010-06-30 |
EP2200431A4 true EP2200431A4 (fr) | 2011-12-21 |
EP2200431B1 EP2200431B1 (fr) | 2016-07-20 |
Family
ID=40452461
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08830619.6A Active EP2190429B1 (fr) | 2007-09-10 | 2008-09-10 | Groupe innovant d'inhibiteurs de la voie stat3 et d'inhibiteurs de la voie des cellules souches cancéreuses |
EP16156335.8A Active EP3050566B1 (fr) | 2007-09-10 | 2008-09-10 | Groupe innovant d'inhibiteurs de la voie stat3 et d'inhibiteurs de la voie des cellules souches cancéreuses |
EP16156290.5A Active EP3058941B1 (fr) | 2007-09-10 | 2008-09-10 | Nouveaux inhibiteurs de la voie stat3 et nouveaux inhibiteurs de cellules souches cancéreuses |
EP16156278.0A Active EP3067054B1 (fr) | 2007-09-10 | 2008-09-10 | Compositions et procédés nouveaux pour le traitement du cancer |
EP08830633.7A Active EP2200431B1 (fr) | 2007-09-10 | 2008-09-10 | Compositions et procédés nouveaux pour le traitement du cancer |
EP08830471.2A Active EP2194987B1 (fr) | 2007-09-10 | 2008-09-10 | Nouveaux inhibiteurs de la voie stat3 et nouveaux inhibiteurs de cellules souches cancéreuses |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08830619.6A Active EP2190429B1 (fr) | 2007-09-10 | 2008-09-10 | Groupe innovant d'inhibiteurs de la voie stat3 et d'inhibiteurs de la voie des cellules souches cancéreuses |
EP16156335.8A Active EP3050566B1 (fr) | 2007-09-10 | 2008-09-10 | Groupe innovant d'inhibiteurs de la voie stat3 et d'inhibiteurs de la voie des cellules souches cancéreuses |
EP16156290.5A Active EP3058941B1 (fr) | 2007-09-10 | 2008-09-10 | Nouveaux inhibiteurs de la voie stat3 et nouveaux inhibiteurs de cellules souches cancéreuses |
EP16156278.0A Active EP3067054B1 (fr) | 2007-09-10 | 2008-09-10 | Compositions et procédés nouveaux pour le traitement du cancer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08830471.2A Active EP2194987B1 (fr) | 2007-09-10 | 2008-09-10 | Nouveaux inhibiteurs de la voie stat3 et nouveaux inhibiteurs de cellules souches cancéreuses |
Country Status (15)
Country | Link |
---|---|
US (12) | US8877803B2 (fr) |
EP (6) | EP2190429B1 (fr) |
JP (16) | JP5688840B2 (fr) |
CN (6) | CN101854802B (fr) |
CA (4) | CA2736564A1 (fr) |
CY (3) | CY1117604T1 (fr) |
DK (4) | DK2194987T3 (fr) |
ES (3) | ES2569215T3 (fr) |
HK (3) | HK1148906A1 (fr) |
HR (3) | HRP20160430T1 (fr) |
HU (3) | HUE029111T2 (fr) |
PL (4) | PL2194987T3 (fr) |
PT (2) | PT2200431T (fr) |
SI (3) | SI2194987T1 (fr) |
WO (3) | WO2009036101A1 (fr) |
Families Citing this family (128)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102886045A (zh) | 2005-02-03 | 2013-01-23 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
KR101354828B1 (ko) | 2005-11-04 | 2014-02-18 | 와이어쓰 엘엘씨 | mTOR 저해자, 헤르셉틴, 및/또는 HKI-272의항신생물성 조합 |
EP2190429B1 (fr) * | 2007-09-10 | 2016-04-20 | Boston Biomedical, Inc. | Groupe innovant d'inhibiteurs de la voie stat3 et d'inhibiteurs de la voie des cellules souches cancéreuses |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
US20130331294A1 (en) | 2007-11-09 | 2013-12-12 | Fox Chase Cancer Center | Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders |
WO2009062199A1 (fr) * | 2007-11-09 | 2009-05-14 | Fox Chase Cancer Center | L'interactome des gènes egfr/nedd9/tgf-β et leurs procédés d'utilisation pour l'identification d'agents ayant une efficacité dans le traitement de troubles hyperprolifératifs |
UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
EP3135285B1 (fr) | 2008-06-17 | 2018-08-15 | Wyeth LLC | Combinaisons antinéoplasiques contenant du hki-272 et de la vinorelbine |
EP2307367B1 (fr) | 2008-07-08 | 2014-09-24 | Board of Regents, The University of Texas System | Nouveaux inhibiteurs de la prolifération et d'activation du transducteur de signaux et activateur de la transcription (stats) |
EP2326329B1 (fr) | 2008-08-04 | 2017-01-11 | Wyeth LLC | Combinaisons antinéoplasiques de 4-anilino-3-cyanoquinoléines et de capécitabine |
EP2370082A4 (fr) * | 2008-12-01 | 2012-05-30 | Univ Central Florida Res Found | Composition de médicament cytotoxique pour des cellules de cancer pancréatique |
DK3000467T3 (da) | 2009-04-06 | 2023-03-27 | Wyeth Llc | Behandling med neratinib mod brystkræft |
CN101897979B (zh) * | 2009-05-27 | 2012-08-22 | 上海市计划生育科学研究所 | 治疗***疾病的靶向药物 |
EP2506852A4 (fr) | 2009-12-04 | 2013-06-19 | Univ Texas | Traitement à l'interféron en combinaison avec un blocage de l'activation de stat3 |
TWI523851B (zh) | 2009-12-28 | 2016-03-01 | Yakult Honsha Kk | 1,3,4-oxadiazole-2-carboxamide |
US20110275577A1 (en) * | 2010-01-08 | 2011-11-10 | Moleculin, Llc | Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs |
MX360640B (es) | 2010-03-01 | 2018-11-09 | Tau Therapeutics Llc Star | Diagnosis e imagenologia de cancer. |
DK3108750T3 (en) * | 2010-03-19 | 2018-10-22 | 1Globe Biomedical Co Ltd | NEW RELATIONS AND COMPOSITIONS TARGETED FOR CANCER STAM CELLS |
RU2571661C2 (ru) * | 2010-03-19 | 2015-12-20 | Бостон Байомедикал, Инк. | Новые соединения и композиции для нацеливания на злокачественные стволовые клетки |
AU2011227023B2 (en) * | 2010-03-19 | 2015-05-28 | Boston Biomedical, Inc. | Novel methods for targeting cancer stem cells |
AU2015218436B9 (en) * | 2010-03-19 | 2017-03-09 | Boston Biomedical, Inc. | Novel Methods For Targeting Cancer Stem Cells |
WO2011130677A1 (fr) * | 2010-04-16 | 2011-10-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Inhibiteurs de cellules souches cancéreuses |
US20110301194A1 (en) * | 2010-06-02 | 2011-12-08 | Arqule, Inc. | Method for Determining Treatment Efficacy |
CN103153975B (zh) * | 2010-08-24 | 2016-01-20 | 杭州益尔生物科技有限公司 | 用于疾病治疗的新型萘醌 |
US20130236473A1 (en) * | 2010-09-16 | 2013-09-12 | Osaka University | Therapeutic agents and prophylactic agents for symptoms accompanying autoimmune diseases, inflammatory diseases, allergy diseases and organ transplants |
EP2643001A4 (fr) * | 2010-11-22 | 2014-02-19 | Glaxosmithkline Ip Dev Ltd | Procédé de traitement du cancer |
WO2012071648A1 (fr) * | 2010-11-30 | 2012-06-07 | London Health Sciences Centre Research Inc. | Antagoniste du récepteur egfr pour le traitement d'une cardiopathie |
WO2012078982A2 (fr) * | 2010-12-09 | 2012-06-14 | The Ohio State University | Xzh-5 inhibe la phosphorylation de stat3 constitutive et induite par l'interleukine 6 dans des cellules de carcinome hépatocellulaire humain |
EP2681203A4 (fr) * | 2011-03-04 | 2014-07-30 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co Ltd | Nouveaux esters de 4,9-dihydroxy-naphto[2,3-b]furannes pour traitement thérapeutique de maladies |
KR20120130658A (ko) * | 2011-05-23 | 2012-12-03 | 주식회사 파멥신 | 펩타이드가 융합된 이중표적항체 및 그 용도 |
AU2012268400C1 (en) * | 2011-06-06 | 2016-12-22 | Akebia Therapeutics Inc. | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
WO2013039859A1 (fr) * | 2011-09-12 | 2013-03-21 | Gray Lloyd S | Antagonistes des produits du groupe unigene hs.459642 pour inhiber la prolifération, le développement ou la différenciation des cellules souches comprenant des cellules souches cancéreuses |
JP6286358B2 (ja) * | 2011-11-11 | 2018-02-28 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | プロテアソーム阻害剤に応答するバイオマーカー |
EP2814480A4 (fr) * | 2012-02-17 | 2015-10-28 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co Ltd | Procédé de préparation de suspensions aqueuses de nanoparticules de dérivés d'esters d'acide aliphatique de 4,9-dihydroxy-naphto[2,3-b]furane |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2013166618A1 (fr) * | 2012-05-08 | 2013-11-14 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | Promédicaments de 4,9-dihydroxy-naphto[2,3-b]furanes permettant de contourner la polypharmacorésistance aux anticancéreux |
AU2013280644B2 (en) | 2012-06-26 | 2018-08-02 | Jeffrey A. BACHA | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
CN103705926A (zh) * | 2012-10-08 | 2014-04-09 | 贾力 | 预防原发性肿瘤在手术切除后再转移的药用组合物 |
DE102013003107A1 (de) | 2013-02-25 | 2014-09-11 | Thomas Rühl | Naphthofurandione mit einer 1-Bromalkylgruppe oder einer 1-Hydroxyalkylgruppe in 2-Position und einer Alkylgruppe in 3-Position zum Furanring-Sauerstoff und Verfahren zu deren Herstellung |
JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び/又は副作用を低減するための方法および組成物 |
BR112015025347A2 (pt) * | 2013-04-09 | 2017-07-18 | Boston Biomedical Inc | 2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer |
US10745489B2 (en) | 2013-04-29 | 2020-08-18 | Ogd2 Pharma | Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for Cancer Stem Cells cancer |
CN105339390A (zh) * | 2013-04-29 | 2016-02-17 | Ogd2药物 | 靶向o-乙酰化的gd2神经节苷脂作为针对癌症干细胞的新型治疗和诊断策略 |
WO2015051241A1 (fr) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
CA2925944C (fr) | 2013-10-04 | 2023-01-10 | Infinity Pharmaceuticals, Inc. | Composes heterocycliques et leurs utilisations |
TW201609094A (zh) * | 2014-01-27 | 2016-03-16 | 波士頓生醫公司 | 治療癌症之新穎方法 |
JP6695275B2 (ja) * | 2014-02-07 | 2020-05-20 | ボストン バイオメディカル, インコーポレイテッド | 3−置換カルボニル−ナフト[2,3−b]フラン誘導体又はその薬学的に許容される塩 |
US11406707B2 (en) | 2014-02-10 | 2022-08-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | STAT3 phosphorylation during graft-versus-host disease |
EP4066834A1 (fr) | 2014-03-19 | 2022-10-05 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques pour une utilisation dans le traitement de troubles à médiation pi3k-gamma |
CA2943640A1 (fr) * | 2014-03-26 | 2015-10-01 | Tocagen Inc. | Vecteur retroviral a activite de stimulation immunitaire |
WO2015164870A1 (fr) | 2014-04-25 | 2015-10-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibiteurs de gamma-aa-peptide stat3/adn et procédés d'utilisation |
US20170266182A1 (en) * | 2014-05-09 | 2017-09-21 | The Brigham And Women's Hospital, Inc. | Treatment of IgG-Immune Complex-Mediated Organ Damage |
US10005752B2 (en) | 2014-06-09 | 2018-06-26 | Kyoto Pharmaceutical Industries, Ltd. | Anticancer agent |
CA2955177A1 (fr) * | 2014-07-15 | 2016-01-21 | The Johns Hopkins University | Suppression de cellules suppressives d'origine myeloide et blocage de point de controle immunitaire |
WO2016054491A1 (fr) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
KR20160066490A (ko) * | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
CN113501826A (zh) | 2015-01-08 | 2021-10-15 | 美国政府健康及人类服务部 | 作为tdp2的抑制剂的呋喃并喹啉二酮 |
EP3274346A1 (fr) | 2015-03-27 | 2018-01-31 | Boston Biomedical, Inc. | Promédicaments solubles dans l'eau |
CN104725480A (zh) * | 2015-04-06 | 2015-06-24 | 苏州普罗达生物科技有限公司 | 一种信号传导及转录激活因子抑制多肽及其应用 |
CN104693279A (zh) * | 2015-04-06 | 2015-06-10 | 苏州普罗达生物科技有限公司 | 关于信号传导及转录激活因子抑制多肽及其应用 |
CN104693280A (zh) * | 2015-04-06 | 2015-06-10 | 苏州普罗达生物科技有限公司 | 信号传导及转录激活因子抑制多肽及其应用 |
US20180085341A1 (en) | 2015-04-17 | 2018-03-29 | Boston Biomedical, Inc. | Methods for treating cancer |
JP2018511642A (ja) * | 2015-04-17 | 2018-04-26 | ボストン バイオメディカル, インコーポレイテッド | 癌を治療するための方法 |
WO2016168857A1 (fr) * | 2015-04-17 | 2016-10-20 | Boston Biomedical, Inc. | Méthodes de traitement du cancer |
EP3288552A1 (fr) * | 2015-04-27 | 2018-03-07 | Boston Biomedical, Inc. | Méthodes de traitement du cancer à l'aide d'un inhibiteur de la voie stat3 et d'un inhibiteur de kinases |
KR20180021697A (ko) * | 2015-05-14 | 2018-03-05 | 뉴카나 피엘씨 | 암 치료 |
JP6949726B2 (ja) * | 2015-05-15 | 2021-10-13 | ノバルティス アーゲー | Egfr変異癌を治療する方法 |
WO2016196935A1 (fr) * | 2015-06-03 | 2016-12-08 | Boston Biomedical, Inc. | Compositions comprenant un inhibiteur des propriétes de type cellules souches de cancers et un agent immunothérapeutique pour une utilisation dans le traitement du cancer |
JP6810036B2 (ja) * | 2015-07-17 | 2021-01-06 | 大日本住友製薬株式会社 | 2−アセチル−4H,9H−ナフト[2,3−b]フラン−4,9−ジオンの製造方法 |
WO2017013270A1 (fr) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Utilisation d'un inhibiteur de la signalisation de la leptine pour la protection des reins de patients atteints de ciliopathie |
WO2017023866A1 (fr) * | 2015-07-31 | 2017-02-09 | Boston Biomedical, Inc. | Procédé de ciblage de stat3 et d'autres protéines non thérapeutiques |
CN108349985A (zh) | 2015-09-14 | 2018-07-31 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
US10660912B2 (en) | 2015-10-05 | 2020-05-26 | NuCana plc | Combination therapy for cancer |
US20190017054A1 (en) * | 2016-01-07 | 2019-01-17 | Luni Emdad | Method of modulating survival and stemness of cancer stem cells by mda-9/syntenin (sdcbp) |
WO2017132049A1 (fr) | 2016-01-20 | 2017-08-03 | Boston Biomedical, Inc. | Méthodes de traitement du cancer |
US11434229B2 (en) | 2016-03-01 | 2022-09-06 | Academia Sinica | 4,9-dioxo-4,9-dihydronaphtho[2,3-b]furan-3-carboxamide derivatives and uses thereof for treating proliferative diseases and infectious diseases |
US10295527B2 (en) | 2016-03-14 | 2019-05-21 | Bruce Yacyshyn | Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis |
US11946927B2 (en) | 2016-03-14 | 2024-04-02 | Musidora Biotechnology Llc | Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
JP6936214B2 (ja) | 2016-03-25 | 2021-09-15 | 大日本住友製薬株式会社 | 2−アルキルカルボニルナフト[2,3−b]フラン−4,9−ジオンの関連物質の製造方法、及びその関連物質 |
JP2017171640A (ja) * | 2016-03-25 | 2017-09-28 | 学校法人兵庫医科大学 | 癌の治療システム |
CN105906595A (zh) * | 2016-04-23 | 2016-08-31 | 陈斌 | 丙酸倍氯米松的药物组合物及其在生物医药中的应用 |
CN105837541A (zh) * | 2016-04-23 | 2016-08-10 | 何淑琼 | 磷酸苯丙哌林的药物组合物及其在生物医药中的应用 |
GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
JP2019519573A (ja) | 2016-06-28 | 2019-07-11 | ボストン バイオメディカル, インコーポレイテッド | がんを処置するための方法 |
CN106380456B (zh) * | 2016-08-29 | 2019-03-26 | 中南大学 | 一种合成苯并呋喃萘醌衍生物的方法 |
WO2018098352A2 (fr) | 2016-11-22 | 2018-05-31 | Jun Oishi | Ciblage d'expression du point de contrôle immunitaire induit par kras |
WO2018096401A1 (fr) | 2016-11-22 | 2018-05-31 | Hitoshi Ban | Nouveaux dérivés de naphtho[2,3-b]furane |
JP7106563B2 (ja) * | 2016-11-29 | 2022-07-26 | スミトモ ファーマ オンコロジー, インコーポレイテッド | ナフトフラン誘導体、その調製、および使用方法 |
BR112019011033A2 (pt) * | 2016-11-30 | 2019-10-15 | Tyme Inc | composição, método para reduzir a proliferação celular em um indivíduo, método para tratar câncer em um indivíduo e kit |
CN113769097A (zh) * | 2017-01-22 | 2021-12-10 | 江苏恒瑞医药股份有限公司 | Egfr/her2抑制剂联合嘧啶类抗代谢药物的用途 |
WO2018183908A1 (fr) * | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Compositions et méthodes de traitement de tumeurs ovariennes |
US10646464B2 (en) | 2017-05-17 | 2020-05-12 | Boston Biomedical, Inc. | Methods for treating cancer |
WO2018225062A1 (fr) * | 2017-06-04 | 2018-12-13 | Rappaport Family Institute For Research In The Medical Sciences | Procédé de prédiction de réponse personnalisée à une thérapie anticancéreuse et kit associé |
CN111132614A (zh) * | 2017-07-20 | 2020-05-08 | 路易斯安娜州立大学监测委员会,农业和机械学院 | 使用脉冲磁场梯度对恶性癌细胞的靶向渗透裂解 |
CN111295368A (zh) | 2017-09-22 | 2020-06-16 | 大日本住友制药株式会社 | 化学活化型水溶性前药 |
EP3710050A4 (fr) * | 2017-11-16 | 2021-06-16 | TyrNovo Ltd. | Combinaisons de modulateurs doubles de irs/stat3 et d'anticorps anti-pd-1/pd-l1 pour le traitement du cancer |
EP3501511A1 (fr) * | 2017-12-22 | 2019-06-26 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos III | Moyens pour la prévention et le traitement de métastases cérébrales |
CN111542598A (zh) * | 2017-12-28 | 2020-08-14 | 株式会社钟化 | 多能干细胞聚集抑制剂 |
CN107973788B (zh) * | 2018-01-09 | 2021-07-09 | 沈阳药科大学 | Bbi608衍生物及其制备与用途 |
FI3770162T3 (fi) | 2018-03-20 | 2023-06-02 | Sumitomo Pharma Co Ltd | Dihydrokromeenijohdannainen |
WO2019232214A1 (fr) | 2018-05-31 | 2019-12-05 | Boston Biomedical, Inc. | Procédés d'utilisation de la napabucasine |
CA3113408A1 (fr) * | 2018-09-18 | 2020-03-26 | Kabushiki Kaisha Yakult Honsha | Polytherapie anticancereuse utilisant un derive de quinoleine carboxamide |
BR112021006898A2 (pt) * | 2018-10-12 | 2021-07-20 | 1Globe Biomedical Co., Ltd. | nova solução de combinação para tratar câncer refratário à quimioterapia |
CN109288845A (zh) * | 2018-10-31 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种咔唑类stat抑制剂马来酸盐晶型ii联合用药物组合物及其制备方法 |
CN109288847A (zh) * | 2018-10-31 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和咔唑类stat抑制剂甲磺酸盐晶型p联合用药物组合物 |
CN109172563A (zh) * | 2018-10-31 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | 一种噻吨酮类紫杉醇和stat3抑制剂联合用药物组合物 |
CN109223758A (zh) * | 2018-10-31 | 2019-01-18 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和芴类stat3抑制剂联合用药物组合物 |
CN109846888A (zh) * | 2018-10-31 | 2019-06-07 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和吲哚类stat3抑制剂联合用药物组合物 |
CN109331004A (zh) * | 2018-10-31 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂甲磺酸盐A晶型联合用药物组合物 |
CN109200044A (zh) * | 2018-10-31 | 2019-01-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂酒石酸盐联合用药物组合物 |
CN109966297A (zh) * | 2018-10-31 | 2019-07-05 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和咔唑类stat抑制剂马来酸盐晶型i联合用药物组合物 |
CN109200052A (zh) * | 2018-10-31 | 2019-01-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和芴酮类stat3抑制剂联合用药物组合物 |
CN109288846A (zh) * | 2018-10-31 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和咔唑类stat3抑制剂晶型a联合用药物组合物 |
CN109364252B (zh) * | 2018-11-21 | 2021-09-28 | 南京大学 | 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用 |
CA3136230A1 (fr) * | 2019-04-09 | 2020-10-15 | Generos Biopharma Ltd. | Combinaison pharmaceutique de pimozide et de methotrexate et utilisation correspondante |
US11564913B2 (en) * | 2019-05-03 | 2023-01-31 | Children's Hospital Medical Center | Compositions and methods for treating cancer |
CN110218198B (zh) * | 2019-05-22 | 2022-06-28 | 广州中医药大学(广州中医药研究院) | 一种萘醌并三氮唑核心骨架衍生物化合物及其制备方法和应用 |
US20220315551A1 (en) * | 2019-06-14 | 2022-10-06 | Sumitomo Dainippon Pharma Co., Ltd. | 2-ALKYLCARBONYL[2,3-b]FURAN-4,9-DIONE PRODUCTION METHOD AND PRODUCTION INTERMEDIATE THEREFOR |
JP7287929B2 (ja) * | 2019-09-25 | 2023-06-06 | 住友ファーマ株式会社 | ジヒドロクロメン誘導体を含有する医薬 |
CA3158371A1 (fr) * | 2019-11-20 | 2021-05-27 | Dianqing Wu | Composes, compositions et methodes de traitement d'une lesion d'ischemie-reperfusion et/ou d'une lesion pulmonaire |
AU2020398177A1 (en) * | 2019-12-05 | 2022-07-07 | Board Of Regents, The University Of Texas System | Exosomes-based therapy for liver fibrosis and other diseases associated with fibrosis |
WO2021185234A1 (fr) * | 2020-03-16 | 2021-09-23 | 正大天晴药业集团股份有限公司 | Composition pharmaceutique combinée de composé en tant qu'inhibiteur de kinase c-met et son utilisation |
US20230192601A1 (en) * | 2020-05-11 | 2023-06-22 | Purdue Research Foundation | Scaled-up synthesis of lomustine under control flow conditions |
CN114286684B (zh) * | 2020-07-27 | 2024-01-05 | 华中科技大学 | 与stat3相关的疾病的预防和/或治疗 |
WO2022216930A1 (fr) * | 2021-04-08 | 2022-10-13 | Virginia Commonwealth University | Nouvel antagoniste de mda -9 à potentiel anti-métastatique |
CN114591306B (zh) * | 2022-03-03 | 2024-03-01 | 陕西中医药大学 | 一种1,2,4-***环的1,4萘醌类stat3抑制剂及其应用 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000044774A2 (fr) * | 1999-01-27 | 2000-08-03 | The University Of South Florida | Inhibition de la transduction du signal par la stat3 pour une therapie anticancereuse chez l'homme |
WO2004026253A2 (fr) * | 2002-09-17 | 2004-04-01 | Arqule, Inc. | Nouveaux composes de lapacho et procedes d'utilisation associes |
WO2005033048A2 (fr) * | 2003-09-29 | 2005-04-14 | The Johns Hopkins University | Antagonistes de voie wnt |
WO2005058829A1 (fr) * | 2003-12-11 | 2005-06-30 | Board Of Regents, The University Of Texas System | Composes pour traiter des maladies associees a une proliferation cellulaire |
WO2005110477A2 (fr) * | 2004-04-09 | 2005-11-24 | University Of South Florida | Polytherapies pour le cancer et des angiopathies proliferantes |
WO2006056399A2 (fr) * | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinaisons d'inhibiteurs de kinase jak |
WO2006113790A2 (fr) * | 2005-04-18 | 2006-10-26 | The Regents Of The University Of Michigan | Compositions et procedes pour le traitement du cancer |
US20070123502A1 (en) * | 2004-12-23 | 2007-05-31 | University Of South Florida | Platinum IV complex inhibitor |
WO2007100640A2 (fr) * | 2006-02-21 | 2007-09-07 | The Regents Of The University Of Michigan | Traitement du cancer a l'aide d'antagonistes du recepteur de l'hormone de croissance |
WO2007115269A2 (fr) * | 2006-03-31 | 2007-10-11 | The Board Of Regents Of The University Of Texas System | Médicaments anticancéreux biodisponibles par voie orale associés à l'acide caféique |
WO2008077062A2 (fr) * | 2006-12-19 | 2008-06-26 | Board Of Regents, The University Of Texas System | Suppression de la réactivation de la stat3 après inhibition de la kinase src pour le traitement du cancer |
WO2008094321A2 (fr) * | 2006-10-04 | 2008-08-07 | Universtiy Of South Florida | Sensibilisation de cellules cancéreuses à l'akt |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2472133A (en) * | 1947-03-20 | 1949-06-07 | Du Pont | Thiophanthraquinone derivatives |
SU1049490A1 (ru) | 1982-05-18 | 1983-10-23 | Ордена Трудового Красного Знамени Институт Химии Ан Мсср | (3 @ ,9 @ ,9 @ )-6,6,9 @ -Триметилтранспергидронафто(2,1- @ )фуран,в качестве душистого компонента парфюмерной композиции |
JPS616149A (ja) | 1984-06-20 | 1986-01-11 | Mitsubishi Electric Corp | 無機絶縁体の製法 |
JPS63196576A (ja) * | 1987-02-10 | 1988-08-15 | Tetsuo Ikegawa | フラルナフトキノン誘導体と制癌剤及びその製造方法 |
EP0309926A3 (fr) | 1987-09-29 | 1990-12-05 | Siemens Aktiengesellschaft | Méthode pour fabriquer des circuits, dont les paramètres peuvent être entièrement spécifiés, dans la technologie de circuits intégrés |
JPH01121284A (ja) | 1987-11-06 | 1989-05-12 | Eisai Co Ltd | トコフェロール n,n−ジアルキルアミノアルキルカルボン酸エステルの胆汁酸塩 |
EP0402192A1 (fr) | 1989-05-31 | 1990-12-12 | BODET, Jean Augustin | Article en carton ou matière analogue et procédé de fabrication |
JPH04139177A (ja) | 1989-12-28 | 1992-05-13 | Dainippon Ink & Chem Inc | フラルベンゾキノン誘導体及びその製造方法並びに制癌剤 |
DE69131875T2 (de) * | 1990-07-10 | 2000-06-15 | Canon Kk | Elektrophotographisches photoempfindliches Element |
JP2942015B2 (ja) * | 1990-07-10 | 1999-08-30 | キヤノン株式会社 | 電子写真感光体およびそれを用いた電子写真装置 |
TW252136B (fr) * | 1992-10-08 | 1995-07-21 | Ciba Geigy | |
JP3598168B2 (ja) | 1996-03-18 | 2004-12-08 | 独立行政法人 科学技術振興機構 | 抗ウイルス剤 |
JPH1121284A (ja) | 1997-06-30 | 1999-01-26 | Kotobuki:Kk | フラノナフトキノン誘導体及びこれを含有する医薬 |
JPH1165141A (ja) * | 1997-08-11 | 1999-03-05 | Canon Inc | 電子写真感光体、該電子写真感光体を有するプロセスカ−トリッジ及び電子写真装置 |
US6174913B1 (en) * | 1998-06-05 | 2001-01-16 | The University Of North Carolina At Chapel Hill | Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents |
BRPI0009448B8 (pt) * | 1999-04-01 | 2021-05-25 | Univ Texas | kit para uso no tratamento de uma neoplasia em um mamífero |
US6482943B1 (en) | 1999-04-30 | 2002-11-19 | Slil Biomedical Corporation | Quinones as disease therapies |
ES2228587T3 (es) | 1999-08-02 | 2005-04-16 | F. Hoffmann-La Roche Ag | Retinoides para el tratamiento de enfisema. |
JP2001097860A (ja) | 1999-09-29 | 2001-04-10 | Japan Science & Technology Corp | 抗薬剤耐性菌剤と抗クラミジア剤 |
UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
KR20010100194A (ko) * | 2000-03-13 | 2001-11-14 | 박호군 | 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법 |
AU2002307217A1 (en) | 2001-03-28 | 2002-10-15 | University Of South Florida | Materials and methods for treatment of cancer and identification of anti-cancer compounds |
GB0117696D0 (en) | 2001-07-20 | 2001-09-12 | Bradford Particle Design Plc | Particle information |
WO2003045357A1 (fr) * | 2001-11-27 | 2003-06-05 | Transform Pharmaceuticals, Inc. | Formules pharmaceutiques orales contenant du paclitaxel et des derives, et methodes d'administration de celles-ci |
EP1469733A4 (fr) | 2001-11-29 | 2008-07-23 | Therakos Inc | Methodes permettant de pretraiter un sujet au moyen d'une photopherese extracorporelle et/ou de cellules apoptotiques |
WO2003075917A1 (fr) * | 2002-03-08 | 2003-09-18 | Signal Pharmaceuticals, Inc. | Polytherapie destinee a traiter, prevenir ou gerer des troubles proliferatifs et des cancers |
DK1344533T3 (da) | 2002-03-15 | 2007-01-08 | Natimmune As | Farmaceutiske præparater, der omfatter mannosebindende lectin |
WO2004024145A1 (fr) | 2002-09-10 | 2004-03-25 | Dabur Research Foundation | Action anticancereuse du carvedilol et de ses isomeres |
TWI323662B (en) * | 2002-11-15 | 2010-04-21 | Telik Inc | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
IS6633A (is) | 2002-11-22 | 2004-05-23 | Omega Farma Ehf. | Samsetningar af fínasteríð töflum |
JP2007516693A (ja) | 2003-06-09 | 2007-06-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | 癌の治療および診断のための組成物および方法 |
EP1664070B1 (fr) | 2003-08-13 | 2008-08-13 | University Of South Florida | Procedes d'inhibition de la proliferation de cellules tumorales |
US20050049207A1 (en) | 2003-09-03 | 2005-03-03 | Kaufmann Doug A. | Method of treating and preventing cancer |
JP4750716B2 (ja) | 2003-12-02 | 2011-08-17 | クリーブランド クリニック ファウンデイション | フラジェリンを使用して放射線から保護する方法 |
DE10359828A1 (de) | 2003-12-12 | 2005-07-28 | Zoser B. Dr.Rer.Nat. Salama | CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe |
JP2004224802A (ja) | 2004-04-21 | 2004-08-12 | Japan Science & Technology Agency | 抗菌剤 |
US7560462B2 (en) * | 2004-07-02 | 2009-07-14 | Icos Corporation | Compounds useful for inhibiting CHK1 |
US20070249636A1 (en) * | 2004-08-18 | 2007-10-25 | Astrazeneca Ab | Selected Fused Heterocyclics and Uses Thereof |
MX2007005434A (es) * | 2004-11-08 | 2007-07-10 | Baxter Int | Composiciones de nanoparticulado de inhibidor de tubulina. |
JP2008535785A (ja) * | 2005-02-25 | 2008-09-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Stat3の小分子阻害剤およびその使用 |
JP2006248978A (ja) * | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
JP2006290871A (ja) | 2005-03-16 | 2006-10-26 | Taheebo Japan Kk | 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法 |
WO2006126505A1 (fr) | 2005-05-26 | 2006-11-30 | The University Of Tokyo | Inhibiteur de fonction stat et son application |
WO2007013946A2 (fr) * | 2005-07-20 | 2007-02-01 | University Of South Florida | Procede de prediction de la reactivite a une chimiotherapie et de selection de traitements |
NZ567266A (en) | 2005-10-13 | 2010-09-30 | Orchid Res Lab Ltd | Carbazole derivatives as pSTAT3/IL-6 inhibitors (carvedilol) |
UA96139C2 (uk) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
AR057579A1 (es) * | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
JP2007145680A (ja) | 2005-11-30 | 2007-06-14 | Idemitsu Kosan Co Ltd | 水素発生材料および水素発生方法 |
JP2009521423A (ja) * | 2005-12-24 | 2009-06-04 | バイオチカ テクノロジー リミテッド | 抗癌剤として有用な21−デオキシマクベシン類似体 |
AU2007208494A1 (en) * | 2006-01-12 | 2007-08-02 | Merck Sharp & Dohme Corp. | Fluorinated arylamide derivatives |
WO2007092620A2 (fr) * | 2006-02-09 | 2007-08-16 | Macusight, Inc. | Formulations stables et leurs procedes de preparation et d'utilisation |
AU2007218966A1 (en) * | 2006-02-24 | 2007-08-30 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic) - 1h-phenanthro [9,10-d] imidazoles |
US20070238770A1 (en) | 2006-04-05 | 2007-10-11 | Bristol-Myers Squibb Company | Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations |
JP4077863B1 (ja) | 2007-05-31 | 2008-04-23 | タヒボジャパン株式会社 | 抗癌活性を有する光学活性2−(1−ヒドロキシエチル)−5−ヒドロキシナフト[2,3−b]フラン−4,9−ジオンの製法 |
EP2190429B1 (fr) | 2007-09-10 | 2016-04-20 | Boston Biomedical, Inc. | Groupe innovant d'inhibiteurs de la voie stat3 et d'inhibiteurs de la voie des cellules souches cancéreuses |
WO2009060282A2 (fr) | 2007-11-06 | 2009-05-14 | Orchid Research Laboratories Limited | Dérivés de stilbène en tant qu'inhibiteurs de pstat3/il-6 |
AU2011227023B2 (en) | 2010-03-19 | 2015-05-28 | Boston Biomedical, Inc. | Novel methods for targeting cancer stem cells |
DK3108750T3 (en) | 2010-03-19 | 2018-10-22 | 1Globe Biomedical Co Ltd | NEW RELATIONS AND COMPOSITIONS TARGETED FOR CANCER STAM CELLS |
RU2571661C2 (ru) | 2010-03-19 | 2015-12-20 | Бостон Байомедикал, Инк. | Новые соединения и композиции для нацеливания на злокачественные стволовые клетки |
AU2015218436B9 (en) | 2010-03-19 | 2017-03-09 | Boston Biomedical, Inc. | Novel Methods For Targeting Cancer Stem Cells |
EP2681203A4 (fr) | 2011-03-04 | 2014-07-30 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co Ltd | Nouveaux esters de 4,9-dihydroxy-naphto[2,3-b]furannes pour traitement thérapeutique de maladies |
US8977803B2 (en) | 2011-11-21 | 2015-03-10 | Western Digital Technologies, Inc. | Disk drive data caching using a multi-tiered memory |
WO2013166618A1 (fr) | 2012-05-08 | 2013-11-14 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | Promédicaments de 4,9-dihydroxy-naphto[2,3-b]furanes permettant de contourner la polypharmacorésistance aux anticancéreux |
BR112015025347A2 (pt) | 2013-04-09 | 2017-07-18 | Boston Biomedical Inc | 2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer |
US20180085341A1 (en) | 2015-04-17 | 2018-03-29 | Boston Biomedical, Inc. | Methods for treating cancer |
JP2018511642A (ja) | 2015-04-17 | 2018-04-26 | ボストン バイオメディカル, インコーポレイテッド | 癌を治療するための方法 |
WO2016168857A1 (fr) | 2015-04-17 | 2016-10-20 | Boston Biomedical, Inc. | Méthodes de traitement du cancer |
EP3288552A1 (fr) | 2015-04-27 | 2018-03-07 | Boston Biomedical, Inc. | Méthodes de traitement du cancer à l'aide d'un inhibiteur de la voie stat3 et d'un inhibiteur de kinases |
WO2016196935A1 (fr) | 2015-06-03 | 2016-12-08 | Boston Biomedical, Inc. | Compositions comprenant un inhibiteur des propriétes de type cellules souches de cancers et un agent immunothérapeutique pour une utilisation dans le traitement du cancer |
WO2017132049A1 (fr) | 2016-01-20 | 2017-08-03 | Boston Biomedical, Inc. | Méthodes de traitement du cancer |
US10646464B2 (en) | 2017-05-17 | 2020-05-12 | Boston Biomedical, Inc. | Methods for treating cancer |
-
2008
- 2008-09-10 EP EP08830619.6A patent/EP2190429B1/fr active Active
- 2008-09-10 WO PCT/US2008/075906 patent/WO2009036101A1/fr active Application Filing
- 2008-09-10 PL PL08830471T patent/PL2194987T3/pl unknown
- 2008-09-10 SI SI200831626A patent/SI2194987T1/sl unknown
- 2008-09-10 SI SI200831606A patent/SI2190429T1/sl unknown
- 2008-09-10 HU HUE08830633A patent/HUE029111T2/en unknown
- 2008-09-10 WO PCT/US2008/075903 patent/WO2009036099A1/fr active Application Filing
- 2008-09-10 SI SI200831655A patent/SI2200431T1/sl unknown
- 2008-09-10 CA CA2736564A patent/CA2736564A1/fr not_active Abandoned
- 2008-09-10 US US12/677,511 patent/US8877803B2/en not_active Expired - Fee Related
- 2008-09-10 ES ES08830619.6T patent/ES2569215T3/es active Active
- 2008-09-10 CN CN200880115249.XA patent/CN101854802B/zh active Active
- 2008-09-10 EP EP16156335.8A patent/EP3050566B1/fr active Active
- 2008-09-10 HU HUE08830619A patent/HUE027443T2/en unknown
- 2008-09-10 EP EP16156290.5A patent/EP3058941B1/fr active Active
- 2008-09-10 US US12/677,513 patent/US9745278B2/en active Active
- 2008-09-10 US US12/677,516 patent/US9732055B2/en active Active
- 2008-09-10 ES ES08830633.7T patent/ES2584904T3/es active Active
- 2008-09-10 EP EP16156278.0A patent/EP3067054B1/fr active Active
- 2008-09-10 CN CN200880115250.2A patent/CN101854930B/zh active Active
- 2008-09-10 CA CA2736563A patent/CA2736563C/fr not_active Expired - Fee Related
- 2008-09-10 DK DK08830471.2T patent/DK2194987T3/en active
- 2008-09-10 PT PT88306337T patent/PT2200431T/pt unknown
- 2008-09-10 JP JP2010524243A patent/JP5688840B2/ja not_active Expired - Fee Related
- 2008-09-10 EP EP08830633.7A patent/EP2200431B1/fr active Active
- 2008-09-10 CN CN201410583457.XA patent/CN104586832B/zh active Active
- 2008-09-10 DK DK16156335.8T patent/DK3050566T3/en active
- 2008-09-10 PT PT88304712T patent/PT2194987T/pt unknown
- 2008-09-10 CN CN201310052882.1A patent/CN103288787B/zh active Active
- 2008-09-10 PL PL08830619.6T patent/PL2190429T3/pl unknown
- 2008-09-10 CA CA2736532A patent/CA2736532C/fr not_active Expired - Fee Related
- 2008-09-10 JP JP2010524251A patent/JP5872160B2/ja not_active Expired - Fee Related
- 2008-09-10 CN CN2008801152470A patent/CN101854937B/zh active Active
- 2008-09-10 WO PCT/US2008/075848 patent/WO2009036059A2/fr active Application Filing
- 2008-09-10 PL PL16156278T patent/PL3067054T3/pl unknown
- 2008-09-10 HU HUE08830471A patent/HUE027657T2/en unknown
- 2008-09-10 DK DK08830619.6T patent/DK2190429T3/en active
- 2008-09-10 JP JP2010524249A patent/JP5701603B2/ja not_active Expired - Fee Related
- 2008-09-10 ES ES08830471.2T patent/ES2583010T3/es active Active
- 2008-09-10 CN CN201610134121.4A patent/CN105963289B/zh active Active
- 2008-09-10 PL PL08830633T patent/PL2200431T3/pl unknown
- 2008-09-10 DK DK08830633.7T patent/DK2200431T3/en active
- 2008-09-10 CA CA2911990A patent/CA2911990C/fr not_active Expired - Fee Related
- 2008-09-10 EP EP08830471.2A patent/EP2194987B1/fr active Active
-
2011
- 2011-03-28 HK HK11103107.1A patent/HK1148906A1/xx unknown
- 2011-03-28 HK HK11103100.8A patent/HK1148942A1/zh unknown
- 2011-03-28 HK HK11103106.2A patent/HK1148943A1/xx unknown
-
2014
- 2014-09-02 JP JP2014177915A patent/JP5938072B2/ja not_active Expired - Fee Related
- 2014-09-02 JP JP2014177908A patent/JP5925849B2/ja not_active Expired - Fee Related
- 2014-09-29 US US14/499,299 patent/US9834532B2/en active Active
- 2014-11-17 JP JP2014232396A patent/JP6106149B2/ja not_active Expired - Fee Related
- 2014-11-17 JP JP2014232397A patent/JP2015034179A/ja not_active Withdrawn
-
2015
- 2015-11-26 JP JP2015230291A patent/JP6358659B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-13 JP JP2016004076A patent/JP6347795B2/ja not_active Expired - Fee Related
- 2016-02-01 JP JP2016016973A patent/JP6346628B2/ja not_active Expired - Fee Related
- 2016-04-21 HR HRP20160430TT patent/HRP20160430T1/hr unknown
- 2016-05-11 CY CY20161100393T patent/CY1117604T1/el unknown
- 2016-05-16 JP JP2016097607A patent/JP2016147906A/ja not_active Withdrawn
- 2016-06-07 HR HRP20160625TT patent/HRP20160625T1/hr unknown
- 2016-07-19 CY CY20161100701T patent/CY1118476T1/el unknown
- 2016-07-26 CY CY20161100733T patent/CY1117833T1/el unknown
- 2016-07-26 HR HRP20160949TT patent/HRP20160949T1/hr unknown
-
2017
- 2017-02-10 US US15/429,939 patent/US20170197932A1/en not_active Abandoned
- 2017-07-11 US US15/647,054 patent/US20180030021A1/en not_active Abandoned
- 2017-07-20 US US15/655,366 patent/US20180030022A1/en not_active Abandoned
- 2017-12-19 JP JP2017242778A patent/JP2018076349A/ja not_active Withdrawn
-
2018
- 2018-05-29 JP JP2018102234A patent/JP2018131464A/ja not_active Withdrawn
- 2018-10-16 US US16/161,413 patent/US10851075B2/en active Active
- 2018-12-31 US US16/236,948 patent/US20200039948A1/en not_active Abandoned
-
2019
- 2019-01-14 US US16/246,829 patent/US10377731B2/en not_active Expired - Fee Related
- 2019-02-21 JP JP2019029436A patent/JP2019073560A/ja active Pending
-
2020
- 2020-05-14 JP JP2020085065A patent/JP2020117547A/ja active Pending
- 2020-05-15 US US16/875,479 patent/US20210024482A1/en not_active Abandoned
- 2020-05-26 JP JP2020091326A patent/JP2020143135A/ja active Pending
- 2020-10-09 US US17/066,885 patent/US20210115006A1/en not_active Abandoned
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000044774A2 (fr) * | 1999-01-27 | 2000-08-03 | The University Of South Florida | Inhibition de la transduction du signal par la stat3 pour une therapie anticancereuse chez l'homme |
WO2004026253A2 (fr) * | 2002-09-17 | 2004-04-01 | Arqule, Inc. | Nouveaux composes de lapacho et procedes d'utilisation associes |
WO2005033048A2 (fr) * | 2003-09-29 | 2005-04-14 | The Johns Hopkins University | Antagonistes de voie wnt |
WO2005058829A1 (fr) * | 2003-12-11 | 2005-06-30 | Board Of Regents, The University Of Texas System | Composes pour traiter des maladies associees a une proliferation cellulaire |
WO2005110477A2 (fr) * | 2004-04-09 | 2005-11-24 | University Of South Florida | Polytherapies pour le cancer et des angiopathies proliferantes |
WO2006056399A2 (fr) * | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinaisons d'inhibiteurs de kinase jak |
US20070123502A1 (en) * | 2004-12-23 | 2007-05-31 | University Of South Florida | Platinum IV complex inhibitor |
WO2006113790A2 (fr) * | 2005-04-18 | 2006-10-26 | The Regents Of The University Of Michigan | Compositions et procedes pour le traitement du cancer |
WO2007100640A2 (fr) * | 2006-02-21 | 2007-09-07 | The Regents Of The University Of Michigan | Traitement du cancer a l'aide d'antagonistes du recepteur de l'hormone de croissance |
WO2007115269A2 (fr) * | 2006-03-31 | 2007-10-11 | The Board Of Regents Of The University Of Texas System | Médicaments anticancéreux biodisponibles par voie orale associés à l'acide caféique |
WO2008094321A2 (fr) * | 2006-10-04 | 2008-08-07 | Universtiy Of South Florida | Sensibilisation de cellules cancéreuses à l'akt |
WO2008077062A2 (fr) * | 2006-12-19 | 2008-06-26 | Board Of Regents, The University Of Texas System | Suppression de la réactivation de la stat3 après inhibition de la kinase src pour le traitement du cancer |
Non-Patent Citations (13)
Title |
---|
COLMAN ET AL.: "Effect of a small molecule inhibitor of the JAK2/STAT3 pathway on self-renewal of glioblastoma stem cells", JOURNAL OF CLINICAL ONCOLOGY, vol. 26, no. 15S, May 2008 (2008-05-01), XP002661523, Retrieved from the Internet <URL:http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/2003?sid=22d20bba-d0ca-4739-a434-779df098ec93> [retrieved on 20101017] * |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CHEN, CHENG CHANG ET AL: "Constituents of Markhamia hildebrandtii (Baker) Sprague and their antitumor activity", XP002661423, retrieved from STN Database accession no. 1986:568912 * |
DESMOND JULIAN C ET AL: "The synthetic furanonaphthoquinone induces growth arrest, apoptosis and differentiation in a variety of leukaemias and multiple myeloma cells", BRITISH JOURNAL OF HAEMATOLOGY, vol. 131, no. 4, November 2005 (2005-11-01), pages 520 - 529, XP002661429, ISSN: 0007-1048 * |
FRANK DAVID A: "STAT3 as a central mediator of neoplastic cellular transformation", CANCER LETTERS, vol. 251, no. 2, June 2007 (2007-06-01), pages 199 - 210, XP022059608, ISSN: 0304-3835 * |
JOHNSON FAYE M ET AL: "Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 13, no. 14, 15 July 2007 (2007-07-15), pages 4233 - 4244, XP002661521, ISSN: 1078-0432 * |
KATOH MASUKO ET AL: "STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer (Review)", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 19, no. 2, 1 February 2007 (2007-02-01), SPANDIDOS PUBLICATIONS, GR, pages 273 - 278, XP009090900, ISSN: 1107-3756 * |
KIM KWANG WOON ET AL: "Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation", MOLECULAR CANCER THERAPEUTICS, vol. 5, no. 11, November 2006 (2006-11-01), pages 2659 - 2665, XP002661520, ISSN: 1535-7163 * |
See also references of WO2009036101A1 * |
SUN X ET AL: "Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and STI571", BLOOD, vol. 97, no. 7, 1 January 2001 (2001-01-01), AMERICAN SOCIETY OF HEMATOLOGY, US, pages 2008 - 2015, XP001151676, ISSN: 0006-4971, DOI: 10.1182/BLOOD.V97.7.2008 * |
YAO ET AL.: "Experimental study on the growth inhibition of bladder cancer cells by signal conduction blocker AG490", JOURNAL OF CLINICAL UROLOGY, vol. 21, no. 5, May 2006 (2006-05-01), pages 379 - 382, XP002661522 * |
YAU CINDY Y F ET AL: "Inhibition of integrin-linked kinase by QLT0254 inhibits Akt-dependent pathways and is growth inhibitory in orthotopic primary pancreatic cancer xenografts", CANCER RESEARCH, vol. 65, no. 4, 15 February 2005 (2005-02-15), pages 1497 - 1504, XP002661524, ISSN: 0008-5472 * |
ZHOU JIANGBING ET AL: "Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, no. 41, October 2007 (2007-10-01), pages 16158 - 16163, XP002661526, ISSN: 0027-8424 * |
ZHOU JIANGBING ET AL: "Corrections: Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, no. 49, 4 December 2007 (2007-12-04), XP002662722 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160949T1 (hr) | Novi sastavi i metode za liječenje karcinoma | |
IL257681A (en) | Methods and compositions for the treatment of cancer | |
PL2173379T3 (pl) | Kompozycje oraz sposoby leczenia i diagnozowania nowotworu | |
HK1140944A1 (en) | Methods and compositions for treating recurrent cancer | |
IL218987A0 (en) | Methods and compositions for treating cancer | |
HK1159498A1 (en) | Methods and compositions for the treatment of cancer | |
EP2125887A4 (fr) | Compositions et procedes utilises pour le diagnostic et le traitement du cancer | |
HK1137158A1 (en) | Formulations for cancer treatment | |
EP2155249A4 (fr) | Compositions et procédés pour le diagnostic et le traitement du cancer | |
EP2340027A4 (fr) | Procédés et compositions destinés au traitement du cancer | |
EP2049151A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
EP2419136A4 (fr) | Compositions et procédés destinés au traitement du cancer | |
HRP20130642T1 (en) | Methods and compositions for treating cancers | |
EP2176406A4 (fr) | Compositions et procédés de traitement du cancer | |
EP2391363A4 (fr) | Compositions et procédés pour le traitement du cancer | |
EP2150270A4 (fr) | Méthodes et compositions pour traiter le cancer | |
IL204945A0 (en) | Compositions and methods for inhibiting tumor progression | |
EP2437738A4 (fr) | Procédés et compositions pour le traitement du cancer | |
EP2411031A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
GB0707556D0 (en) | Treatment for cancer | |
EP2252298A4 (fr) | Compositions et procédés pour le traitement du cancer du poumon | |
SI3067054T1 (sl) | Novi sestavki in postopki za zdravljenje raka | |
HUE054409T2 (hu) | Új kompozíciók és eljárások rák kezelésére | |
EP2068629A4 (fr) | Compositions et methodes de traitement du cancer | |
GB0700493D0 (en) | Cancer treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100331 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: LI, YOUZHI Inventor name: MIKULE, KEITH Inventor name: LI, CHIANG, JIA |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602008045226 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A01N0031140000 Ipc: A61K0031505000 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20111024BHEP Ipc: A61K 38/17 20060101ALI20111024BHEP Ipc: A61K 31/55 20060101ALI20111024BHEP Ipc: A61K 31/505 20060101AFI20111024BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20111121 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20111115BHEP Ipc: A61K 38/17 20060101ALI20111115BHEP Ipc: A61K 31/55 20060101ALI20111115BHEP Ipc: A61K 31/505 20060101AFI20111115BHEP |
|
17Q | First examination report despatched |
Effective date: 20130916 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20151005 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BOSTON BIOMEDICAL, INC. |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: LI, YOUZHI Inventor name: LI, CHIANG, JIA Inventor name: MIKULE, KEITH |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
INTG | Intention to grant announced |
Effective date: 20160523 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: TUEP Ref document number: P20160949 Country of ref document: HR Ref country code: RO Ref legal event code: EPE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: STOLMAR AND PARTNER INTELLECTUAL PROPERTY S.A., CH Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 2200431 Country of ref document: PT Date of ref document: 20160803 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20160726 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20160812 Ref country code: AT Ref legal event code: REF Ref document number: 813481 Country of ref document: AT Kind code of ref document: T Effective date: 20160815 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008045226 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: EE Ref legal event code: FG4A Ref document number: E012157 Country of ref document: EE Effective date: 20160720 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2584904 Country of ref document: ES Kind code of ref document: T3 Effective date: 20160930 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: T1PR Ref document number: P20160949 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: NO Ref legal event code: T2 Effective date: 20160720 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: T3 Ref document number: E 22172 Country of ref document: SK Ref country code: GR Ref legal event code: EP Ref document number: 20160401718 Country of ref document: GR Effective date: 20161020 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E029111 Country of ref document: HU |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008045226 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20170421 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: RUE DU CENDRIER 15 CP 1489, 1201 GENEVE (CH) |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20160949 Country of ref document: HR Payment date: 20190905 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CY Payment date: 20190827 Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 813481 Country of ref document: AT Kind code of ref document: T Effective date: 20160720 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20160949 Country of ref document: HR Payment date: 20200828 Year of fee payment: 13 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200910 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20160949 Country of ref document: HR Payment date: 20210903 Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20160949 Country of ref document: HR Payment date: 20220831 Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20160949 Country of ref document: HR Payment date: 20230829 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20230901 Year of fee payment: 16 Ref country code: RO Payment date: 20230906 Year of fee payment: 16 Ref country code: NO Payment date: 20230926 Year of fee payment: 16 Ref country code: NL Payment date: 20230920 Year of fee payment: 16 Ref country code: MC Payment date: 20230918 Year of fee payment: 16 Ref country code: LU Payment date: 20230918 Year of fee payment: 16 Ref country code: IE Payment date: 20230828 Year of fee payment: 16 Ref country code: GB Payment date: 20230922 Year of fee payment: 16 Ref country code: FI Payment date: 20230918 Year of fee payment: 16 Ref country code: EE Payment date: 20230915 Year of fee payment: 16 Ref country code: CZ Payment date: 20230828 Year of fee payment: 16 Ref country code: BG Payment date: 20230915 Year of fee payment: 16 Ref country code: AT Payment date: 20230915 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SK Payment date: 20230905 Year of fee payment: 16 Ref country code: SI Payment date: 20230825 Year of fee payment: 16 Ref country code: SE Payment date: 20230922 Year of fee payment: 16 Ref country code: PT Payment date: 20230830 Year of fee payment: 16 Ref country code: PL Payment date: 20230911 Year of fee payment: 16 Ref country code: IS Payment date: 20230925 Year of fee payment: 16 Ref country code: HU Payment date: 20230901 Year of fee payment: 16 Ref country code: HR Payment date: 20230829 Year of fee payment: 16 Ref country code: GR Payment date: 20230915 Year of fee payment: 16 Ref country code: FR Payment date: 20230925 Year of fee payment: 16 Ref country code: DK Payment date: 20230919 Year of fee payment: 16 Ref country code: DE Payment date: 20230928 Year of fee payment: 16 Ref country code: BE Payment date: 20230918 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MT Payment date: 20230919 Year of fee payment: 16 Ref country code: LV Payment date: 20230921 Year of fee payment: 16 Ref country code: LT Payment date: 20230824 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20231019 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230929 Year of fee payment: 16 Ref country code: CH Payment date: 20231001 Year of fee payment: 16 |